{"url":"https://lda.senate.gov/api/v1/filings/f179f378-e0eb-40d3-bacb-217d5e41abfa/","filing_uuid":"f179f378-e0eb-40d3-bacb-217d5e41abfa","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2025,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f179f378-e0eb-40d3-bacb-217d5e41abfa/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Engel Burns","dt_posted":"2025-07-16T16:34:34-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5232 Macomb St NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20016","registrant":{"id":401109779,"url":"https://lda.senate.gov/api/v1/registrants/401109779/","house_registrant_id":77137,"name":"ENGEL BURNS","description":null,"address_1":"5232 Macomb St NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20016","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ENGEL BURNS","contact_telephone":"+1 443-326-8847","dt_updated":"2026-02-25T15:34:05.494133-05:00"},"client":{"id":67858,"url":"https://lda.senate.gov/api/v1/clients/67858/","client_id":67858,"name":"ANNEXON BIOSCIENCES","general_description":"Pharmaceutical manufacturer","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-05-28"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Rare disease policy, drug approval process","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":150483,"prefix":null,"prefix_display":null,"first_name":"ENGEL","nickname":null,"middle_name":null,"last_name":"BURNS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}